1. Home
  2. BMN vs MXCT Comparison

BMN vs MXCT Comparison

Compare BMN & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

BMN

BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

SELL

Current Price

$23.23

Market Cap

145.5M

Sector

Finance

ML Signal

SELL

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.24

Market Cap

155.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BMN
MXCT
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.5M
155.8M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BMN
MXCT
Price
$23.23
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.11
AVG Volume (30 Days)
38.2K
★ 1.4M
Earning Date
01-01-0001
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $33,026,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$10.06
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$21.28
$0.64
52 Week High
$27.96
$1.81

Technical Indicators

Market Signals
Indicator
BMN
MXCT
Relative Strength Index (RSI) 50.97 46.08
Support Level $21.28 $1.19
Resistance Level $25.95 $1.27
Average True Range (ATR) 0.45 0.17
MACD 0.04 -0.04
Stochastic Oscillator 34.52 29.05

Price Performance

Historical Comparison
BMN
MXCT

About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: